Cancer management is a rapidly evolving field, with significant strides being made in the integration of exosomal biomarkers and nanotechnology to enhance early detection and targeted therapy. Despite advancements in treatment, cancer remains a leading cause of morbidity and mortality worldwide, necessitating innovative approaches to improve patient outcomes. Current challenges include the need for non-invasive diagnostic methods and more effective, targeted therapies that minimize side effects. Recent studies have highlighted the potential of liquid biopsies and extracellular vesicle (EV)-associated biomarkers in providing non-invasive cancer detection with high sensitivity and specificity. However, translating these promising technologies from the laboratory to clinical practice remains a significant hurdle, underscoring the need for interdisciplinary collaboration and further research to bridge existing gaps.

This research topic aims to explore the cutting-edge advancements in the integration of biomarkers and nanotechnology for enhancing cancer management. The primary objectives include investigating the development of liquid biopsies and EV-associated biomarkers for non-invasive cancer detection, as well as the design of nano-based diagnostic platforms. Additionally, the research will focus on the role of nanotechnology in creating advanced drug delivery systems that enable targeted therapy, with an emphasis on improving therapeutic efficacy while minimizing side effects. By addressing these objectives, the research seeks to answer critical questions and test hypotheses related to the efficacy and practicality of these innovative strategies in clinical settings.

To gather further insights in the integration of biomarkers and nanotechnology for cancer management, we welcome articles addressing, but not limited to, the following themes:
- Development and validation of liquid biopsy techniques for cancer detection.
- Exploration of extracellular vesicle-associated biomarkers in oncology.
- Design and application of nano-based diagnostic platforms.
- Innovations in nanotechnology for targeted drug delivery systems.
- Challenges and strategies for translating laboratory findings to clinical practice.
- Interdisciplinary collaboration in advancing cancer diagnosis and treatment.
- Case studies highlighting successful integration of these technologies in clinical settings.

Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Submit your idea

Impact

Frontiers in Oncology

Submit your idea

Impact